BRPI0906044A2 - "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" - Google Patents
"mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"Info
- Publication number
- BRPI0906044A2 BRPI0906044A2 BRPI0906044-8A BRPI0906044A BRPI0906044A2 BR PI0906044 A2 BRPI0906044 A2 BR PI0906044A2 BR PI0906044 A BRPI0906044 A BR PI0906044A BR PI0906044 A2 BRPI0906044 A2 BR PI0906044A2
- Authority
- BR
- Brazil
- Prior art keywords
- tnfrp75
- fusion protein
- soluble mutant
- pharmaceutical compositions
- dna sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200810038410XA CN101591388A (zh) | 2008-05-30 | 2008-05-30 | 一种可溶性tnf受体突变体 |
PCT/CN2009/000037 WO2009143689A1 (zh) | 2008-05-30 | 2009-01-12 | 一种可溶性tnf受体突变体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0906044A2 true BRPI0906044A2 (pt) | 2015-07-07 |
Family
ID=41376564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0906044-8A BRPI0906044A2 (pt) | 2008-05-30 | 2009-01-12 | "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" |
Country Status (10)
Country | Link |
---|---|
US (1) | US8454969B2 (pt) |
EP (1) | EP2221314B1 (pt) |
JP (1) | JP5445975B2 (pt) |
KR (1) | KR101243951B1 (pt) |
CN (2) | CN101591388A (pt) |
AU (1) | AU2009253623B2 (pt) |
BR (1) | BRPI0906044A2 (pt) |
CA (1) | CA2710040C (pt) |
RU (1) | RU2478645C2 (pt) |
WO (1) | WO2009143689A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101273893B1 (ko) * | 2010-09-13 | 2013-06-14 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 |
US8754037B2 (en) | 2010-12-23 | 2014-06-17 | Hanall Biopharma Co., Ltd. | Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same |
KR101514238B1 (ko) * | 2012-06-21 | 2015-04-28 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드의 신규 용도 |
CN104561022B (zh) * | 2014-12-22 | 2017-05-17 | 南京师范大学 | 家猪肿瘤坏死因子突变体的构建及蛋白表达纯化方法 |
CN108853482A (zh) * | 2017-05-12 | 2018-11-23 | 上海复旦张江生物医药股份有限公司 | 一种重组人TNFR-Fc融合蛋白突变体的用途 |
TW202229355A (zh) * | 2020-12-11 | 2022-08-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 抗tnfr2抗體及其應用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2288351A1 (en) * | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
IL130608A0 (en) * | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
CN1246337C (zh) * | 2002-11-26 | 2006-03-22 | 广州绿阳生物工程有限公司 | 新型TNFR-Fc融合蛋白 |
US7276477B2 (en) * | 2003-08-01 | 2007-10-02 | Amgen Inc. | Crystals of etanercept and methods of making thereof |
CN101085813B (zh) * | 2006-06-05 | 2012-01-25 | 上海复旦张江生物医药股份有限公司 | 一种可溶性tnf受体突变体 |
CN101003575A (zh) * | 2007-01-12 | 2007-07-25 | 中国医学科学院血液学研究所泰达生命科学技术研究中心 | 人肿瘤坏死因子可溶性受体Ⅱ-抗体Fc段融合蛋白 |
-
2008
- 2008-05-30 CN CNA200810038410XA patent/CN101591388A/zh active Pending
-
2009
- 2009-01-12 EP EP09753407.7A patent/EP2221314B1/en not_active Not-in-force
- 2009-01-12 WO PCT/CN2009/000037 patent/WO2009143689A1/zh active Application Filing
- 2009-01-12 CN CN200980101260.5A patent/CN101883787B/zh active Active
- 2009-01-12 RU RU2010141916/10A patent/RU2478645C2/ru not_active IP Right Cessation
- 2009-01-12 AU AU2009253623A patent/AU2009253623B2/en not_active Ceased
- 2009-01-12 BR BRPI0906044-8A patent/BRPI0906044A2/pt not_active Application Discontinuation
- 2009-01-12 JP JP2010544562A patent/JP5445975B2/ja not_active Expired - Fee Related
- 2009-01-12 CA CA2710040A patent/CA2710040C/en not_active Expired - Fee Related
- 2009-01-12 US US12/745,724 patent/US8454969B2/en not_active Expired - Fee Related
- 2009-01-12 KR KR1020107015346A patent/KR101243951B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US8454969B2 (en) | 2013-06-04 |
CN101883787A (zh) | 2010-11-10 |
EP2221314A4 (en) | 2010-12-29 |
RU2010141916A (ru) | 2012-04-20 |
KR20100135706A (ko) | 2010-12-27 |
JP5445975B2 (ja) | 2014-03-19 |
AU2009253623B2 (en) | 2013-08-22 |
CN101883787B (zh) | 2014-09-10 |
AU2009253623A1 (en) | 2009-12-03 |
KR101243951B1 (ko) | 2013-03-13 |
JP2011511627A (ja) | 2011-04-14 |
RU2478645C2 (ru) | 2013-04-10 |
US20110117082A1 (en) | 2011-05-19 |
CA2710040A1 (en) | 2009-12-03 |
CA2710040C (en) | 2013-05-28 |
CN101591388A (zh) | 2009-12-02 |
EP2221314B1 (en) | 2013-07-03 |
EP2221314A1 (en) | 2010-08-25 |
WO2009143689A1 (zh) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200809394B (en) | Rage fusion proteins, formulations, and methods of use thereof | |
BRPI0908021A2 (pt) | Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica | |
BRPI0607198A2 (pt) | composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica | |
BRPI0913726A2 (pt) | rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos | |
BRPI0812575A2 (pt) | Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, sequência de nucleotídeos | |
BRPI0914549A2 (pt) | produção, formulação de usos de formulações estáveis de proteína harpina líquidas | |
BRPI1011876A2 (pt) | "composição farmacêutica estável e métodos de uso da mesma" | |
IL202443B (en) | Nucleic acid encoding it and a pharmaceutical preparation containing the protein, a fusion protein for nucleic acid | |
IL213039A (en) | Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors | |
CR10619A (es) | Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos | |
BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
BRPI0920026A2 (pt) | método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos. | |
BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos | |
BRPI0915680A2 (pt) | miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos | |
FR2933700B1 (fr) | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique | |
CL2007002376A1 (es) | Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas. | |
BRPI0906044A2 (pt) | "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" | |
IL184558A0 (en) | Sustained release composition of protein drug | |
ZA200900237B (en) | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | |
IL186258A0 (en) | Chimeric proteins, their preparation and pharmaceutical compositions containing them | |
FR2927625B1 (fr) | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique | |
FR2917413B1 (fr) | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
BRPI0910570A2 (pt) | uso de bioconjugados, e, formulações farmacêuticas | |
FR2920774B1 (fr) | Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant | |
FR2930249B1 (fr) | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |